A trading update from RUA Life Sciences (LON: RUA) for the 18 months to September 2025 shows revenues of £6.2m, of which £5.1m were in the most recent 12 month period. A 12 month loss of £1.2m is expected and that should fall sharply this year. The share price rebounded 8.33% to 13p.
In the year to June 2025, Dotdigital (LON: DOTD) increased revenues 6% to £83.9m, after the loss of a contract, while pre-tax profit was £19m. Net cash is £36m. Canaccord Genuity has edged up its 2025-26 pe-tax profit forecast to £19.9m. Dotdigital is well placed to take advantage of growing marketing spending and use of its AI tools. The share price rose 6.32% to 72.3p.
Potash project developer Kore Potash (LON: KP2) has commenced a formal sale process to enable engagement with parties interested in acquiring the company, which is seeking finance for the Kola potash project. The review may decide that Koe Potash should continue as an independent company rather than being acquired. The share price increased 6.45% to 3.3p.
Aptamer Group (LON: APTA) has gained a new contract with an existing top 5 pharma customer. This the third project and it is to develop Optimer binders against three key drug targets and provide support for assay development. Aptamer retains the IP. Aptamer has a signed total contract value of £1.75m. The share price improved 6.25% to 0.85p.
FALLERS
URU Metals (LON: URU) has raised £1.1m from an oversubscribed placing at 7p/share. This will finance development of the recently awarded mining licence for the Zeb Nickel project in South Africa, including important groundwork to prepare for a drilling programme. The mining right has a 30 year term. The share price fell 9.72% to 8.125p.
Digital media company Catenai (LON: CTAI) has repaid a £100,000 working capital loan and 33.3 million warrants exercisable at 0.3p each were issued to the group of lenders. The share price dipped 8.33% to 0.33p.
Cellbxhealth (LON: CLBX) says experts predict that CTC testing will become routine within five years. They provide distinct and impactful information that is not captured by circulating tumour DNA. Two-fifths of the experts identified Parsortix as the most promising next generation technology. The share price declined 5.88% to 2.4p.
Pulsar Helium Inc (LON: PLSR) has signed a definitive agreement for the acquisition of Aquis-quoted Oscillate’s subsidiary Quantum Hydrogen, which holds non-hydrocarbon gas rights in Minnesota. The initial 80% will be bought for $400,000 in shares and the other 20% will be acquired in 18 months for an additional $400,000 in shares. The share price decreased 5.68% to 41.5p.